Journal of Jilin University(Medicine Edition) ›› 2023, Vol. 49 ›› Issue (2): 332-340.doi: 10.13481/j.1671-587X.20230209
• Research in basic medicine • Previous Articles Next Articles
Yifei SUN1,2,Dinuo LI2,Yubin WANG2(
)
Received:2022-04-12
Online:2023-03-28
Published:2023-04-24
Contact:
Yubin WANG
E-mail:wyb641025@163.com
CLC Number:
Yifei SUN,Dinuo LI,Yubin WANG. Inhibitory effect of curcumin on proliferation and invasion of gastric cancer MGC-803 cells by down-regulating PI3K/Akt/mTOR signaling pathway protein expression[J].Journal of Jilin University(Medicine Edition), 2023, 49(2): 332-340.
Tab.1
Proliferation abilities of MGC-803 cells in various groups detected by CCK-8 method"
| Group | Proliferation ability | ||||||
|---|---|---|---|---|---|---|---|
| (t/h) 0 | 24 | 48 | 72 | ||||
| Control | 0.272±0.003 | 0.793±0.012 | 1.125±0.041 | 1.887±0.024 | |||
| Low dose of curcumin | 0.272±0.003 | 0.612±0.011 | 0.864±0.022* | 1.458±0.006* | |||
| Middle dose of curcumin | 0.272±0.003 | 0.493±0.005 | 0.651±0.007*△ | 1.265±0.033* | |||
| High dose of curcumin | 0.272±0.003 | 0.425±0.036*△# | 0.623±0.014*△# | 0.987±0.016*△# | |||
| 1 | 李 婧, 梁何俊, 隋 鑫, 等. Ⅱ/Ⅲ期胃癌术后患者预后预测模型的建立[J].郑州大学学报(医学版),2022,57(2):220-227. |
| 2 | SUN W H, JIANG C Q, JI Y, et al. Long noncoding RNAs: new regulators of resistance to systemic therapies for gastric cancer[J]. Biomed Res Int, 2021, 2021: 8853269. |
| 3 | 高 磊, 俞 阳, 李晓梅, 等. 化疗与免疫检查点抑制剂联用对肿瘤的作用研究进展[J].解放军医学杂志,2022,47(11):1152-1158. |
| 4 | DI VITA M, ZANGHÌ A, CAVALLARO A, et al. Gastric GIST and prognostic models. Which is the best to predict survival after surgery? [J]. Ann Ital Chir, 2019, 90: 31-40. |
| 5 | CUI L, WANG X Q, ZHANG D K. TLRs as a promise target along with immune checkpoint against gastric cancer[J]. Front Cell Dev Biol, 2021, 8: 611444. |
| 6 | LI H Y, YANG M, LI Z, et al. Curcumin inhibits angiotensin Ⅱ-induced inflammation and proliferation of rat vascular smooth muscle cells by elevating PPAR-γ activity and reducing oxidative stress[J]. Int J Mol Med, 2017, 39(5): 1307-1316. |
| 7 | ALQURASHI N, HASHIMI S M, ALOWAIDI F,et al. Dual mTOR/PI3K inhibitor NVP-BEZ235 arrests colorectal cancer cell growth and displays differential inhibition of 4E-BP1[J]. Oncol Rep, 2018,40(2): 1083-1092. |
| 8 | XIE J, FU L P, JIN L. Immunotherapy of gastric cancer: Past, future perspective and challenges[J]. Pathol Res Pract, 2021, 218: 153322. |
| 9 | BAHRAMI A, FERNS G A. Effect of curcumin and its derivates on gastric cancer: molecular mechanisms[J]. Nutr Cancer, 2021, 73(9): 1553-1569. |
| 10 | 叶卫华, 袁虎方. 膜联蛋白A7水平在胃癌患者癌组织及外周血液中的变化及其临床意义[J]. 中国普通外科杂志, 2019, 28(10): 1261-1268. |
| 11 | 陈金湖, 叶 青.黄峰局部进展期胃癌围手术期治疗的发展历程和研究进展[J].中华胃肠外科杂志,2019,22(2):196-200. |
| 12 | 陈海滔, 徐 超, 姚庆华. 姜黄素通过调节Wnt/β-catenin信号通路抑制结肠癌细胞上皮间质转化[J]. 肿瘤学杂志, 2017, 23(1): 35-39. |
| 13 | YUAN H F, LI Y, YE W H, et al. Downregulation of annexin A7 decreases proliferation, migration, and invasion of gastric cancer cells by reducing matrix metalloproteinase 1 and 9 expression[J]. Am J Transl Res, 2019, 11(5): 2754-2764. |
| 14 | 贺东黎. 姜黄素通过ATK/FoxM1信号通路调控胃癌干细胞增殖及凋亡[J].中国组织工程研究,2016,20(32): 4731-4737. |
| 15 | GHAFOURI-FARD S, ABAK A, TONDRO ANAMAG F, et al. The emerging role of non-coding RNAs in the regulation of PI3K/AKT pathway in the carcinogenesis process[J]. Biomed Pharmacother, 2021, 137: 111279. |
| 16 | 崔健昆, 耿乃志, 孟凡吉, 等. 去甲氧基姜黄素通过PI3K-Akt-mTOR信号通路调控细胞自噬对心肌缺血再灌注损伤大鼠的保护作用研究[J]. 中医药学报, 2020, 48(8): 19-24. |
| 17 | WANG C, YANG Z, XU E, et al. Apolipoprotein C-II induces EMT to promote gastric cancer peritoneal metastasis via PI3K/AKT/mTOR pathway[J]. Clin Transl Med, 2021, 11(8): e522. |
| 18 | LIN J X, XIE X S, WENG X F, et al. UFM1 suppresses invasive activities of gastric cancer cells by attenuating the expression of PDK1 through PI3K/AKT signaling[J]. J Exp Clin Cancer Res, 2019, 38(1): 410. |
| 19 | XIAO M, LIN C H, YANG Z X, et al. Compound TDB (Tricyclic decyl benzoxazole) induces autophagy-dependent apoptosis in the gastric cancer cell line MGC-803 by regulating PI3K/AKT/mTOR[J]. Am J Transl Res, 2021, 13(1): 73-87. |
| 20 | WANG H H, MAO J, HUANG Y H, et al. Prognostic roles of miR-124-3p and its target ANXA7 and their effects on cell migration and invasion in hepatocellular carcinoma[J].Int J Clin Exp Pathol,2020,13(3):357-370. |
| 21 | 杜锐玲. 叶黄素通过PI3K/AKT信号通路调控胃癌干细胞增殖与凋亡[J]. 中国组织工程研究, 2019, 23(29): 4593-4598. |
| 22 | 沈 玲, 罗 波. 晚期胃癌二线使用EOX和FOLFIRI方案化疗的疗效及安全性评价[J]. 西安交通大学学报(医学版), 2018, 39(4): 546-550. |
| 23 | 李 琼, 贺延苓, 张志敏. 姜黄素的抗癌生物学机制研究进展[J]. 药物生物技术, 2021, 28(2): 217-220. |
| 24 | 李柯楠, 刘会勤, 丛 宁, 等. PI3K/mTOR双靶点抑制剂PI-103在体外对喉鳞癌细胞的作用[J]. 复旦学报(医学版), 2019, 46(3): 350-356. |
| 25 | ZHANG C, ZHANG M Q, GE S, et al. Reduced m6A modification predicts malignant phenotypes and augmented Wnt/PI3K-Akt signaling in gastric cancer[J]. Cancer Med, 2019, 8(10): 4766-4781. |
| 26 | 念家云, 王笑民, 富 琦, 等. 基于PI3K/Akt/mTOR信号传导通路的抗癌中药单体的研究概况[J]. 中国药房, 2019, 30(20): 2870-2875. |
| 27 | 江孝蓉, 王正根. PI3K/AKT/mTOR信号通路及PI3K/mTOR双重抑制剂在胃癌中的研究进展[J]. 西南军医, 2018, 20(3): 375-379. |
| 28 | 刘 琦, 郝朗松, 张东兴, 等. PI3K/Akt/mTOR信号通路抑制剂在转移性结直肠癌中的研究进展[J]. 医学综述, 2019, 25(14): 2721-2725. |
| 29 | CHRISTENSEN T D, PALSHOF J A, LARSEN F O,et al. Associations between primary tumor RAS, BRAF and PIK3CA mutation status and metastatic site in patients with chemo-resistant metastatic colorectal cancer[J]. Acta Oncol, 2018, 57(8): 1057-1062. |
| 30 | TOWNSEND A, TEBBUTT N, KARAPETIS C,et al.Phase ⅠB/Ⅱ study of second-line therapy with panitumumab, irinotecan, and everolimus (PIE) in KRAS wild-type metastatic colorectal cancer[J]. Clin Cancer Res, 2018, 24(16): 3838-3844. |